Compare NRG Energy Inc (NRG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? NRG Energy Inc trades at $132.3 (market cap $27.55B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.4× NRG Energy Inc's market cap, and NRG Energy Inc pays a 1.46% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NRG | VRTX | |
|---|---|---|
Market Cap | $27.55B | $121.95B |
Sector | Utilities | Health |
52-Week High | $184.03 | $529.59 |
52-Week Low | $120.65 | $366.54 |
Enterprise Value | $51.38B | $116.69B |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $131.60, up 1.93% over 24 hours, with a bearish technical signal despite bullish oscillators. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue grew to $30.71 billion in 2025, though net income margin remains thin at 0.74%. Analyst consensus is strongly bullish with a $217.50 price target, supported by institutional buying interest.
The outlook is cautiously optimistic given strong analyst support and strategic positioning for power demand growth, but risks include volatile cash flows, high debt levels, and execution challenges. The stock offers potential upside if earnings momentum improves, yet investors face headwinds from margin pressure and macroeconomic sensitivity.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
